Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (351-360 of 388) with videos related to

Pageof 39
Sort By:
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trialRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Journal of Clinical Pathology|November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinomaMatteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2015
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Matteo Santoni, Alessandro Conti, Giuseppe Procopio, et al.
Pageof 39

Showing results (351-360 of 388) with videos related to

Sort By:
Pageof 39
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
The New England Journal of Medicine|March 3, 2021
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Mauricio Burotto, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trialRobert J Motzer, Bernard Escudier, David F McDermott, et al.
Journal of Clinical Pathology|November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinomaMatteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2015
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Matteo Santoni, Alessandro Conti, Giuseppe Procopio, et al.
Pageof 39